Products
Platform
Research
Market
Learn
Partner
Support
IPO

A

-- / --

RHP/DRHP

Issue Date

--

Price Range

--

Lot Size

--

IPO Size

N/A

Schedule of Amster Labs IPO

Start date

End date

Allotment of bids

Refund Initiation

Listing on exchange

The IPO of Amster Labs Ltd comprises a fresh issue of up to 53,08,800 equity shares of face value of ₹10 each. There’s no offer for sale in this IPO, which is a 100% book-built issue. The IPO price band is TBA. The lot size is TBA.

The IPO opening date is TBA. The IPO closing date is TBA. The listing of shares will take place on TBA. The allotment of shares will take place on TBA. The credit of shares to the demat account will take place on TBA. The initiation of refunds will take place on TBA.

Amster Labs Ltd is engaged in the business of manufacturing and distribution of pharmaceutical products. It manufactures products for certain third parties who market them under their own brands for already approved products. The company offers a diverse range of pharmaceutical products, including ethical drugs, generic medications, and over-the-counter (OTC) solutions.

  • To set up a new manufacturing unit and unification of existing divisions
  • To meet the working capital requirements of the company
  • To meet out the general corporate purposes
  • To meet out the issue expenses

Market size of the Indian pharmaceuticals industry is expected to reach ~US$ 130 billion by 2030 and US$ 450 billion market by 2047. According to the government data, the Indian pharmaceutical industry is worth approximately US$ 50 billion with over US$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India.

The Indian pharmaceutical industry has seen a massive expansion over the last few years and is expected to reach about 13% of the size of the global pharma market while enhancing its quality, affordability and innovation.

Amster Labs Ltd is engaged in the business of manufacturing and distribution of pharmaceutical products. It manufactures products for certain third parties who market them under their own brands for already approved products. The company offers a diverse range of pharmaceutical products, including ethical drugs, generic medications, and over-the-counter (OTC) solutions.

  • Dependent on Few Customers : Significant portion of its revenues depends upon the order from its key customers and the loss of any of its customers which it caters to may adversely affect its sales and consequently on its business and results of operations.

  • Risks in Manufacturing Process : The company’s business is dependent and will continue to depend on its manufacturing facilities, and is subject to certain risks in its manufacturing process such as the breakdown or failure of equipment, industrial accidents, severe weather conditions and natural disasters.

  • Dependence on Limited Number of Suppliers : The company relies on limited suppliers for raw materials with whom it generally does not enter into any long-term supply contract or agreements. The order for the materials is placed on a requirement basis. If there are any delays or disruptions in the supply of these materials from its suppliers, its ability to deliver the products may be affected.

Loading chart...

TBA

  • IPO Registrar: Skyline Financial Services Pvt Ltd
  • Book Running Lead Manager: Fast Track Finsec Pvt Ltd

The company offers a diverse range of pharmaceutical products, including ethical drugs, generic medications, and over-the-counter (OTC) solutions. Its extensive portfolio features Softgel Capsules, Herbal Soft Gelatin Capsules, Carotenoids Soft Gelatin Capsules, Calcitriol Soft Gelatin Capsules, Oil Soft Gel Capsules, and more.

Additionally, the company specialises in pharmaceutical formulations such as General & Beta Lactam Tablets, oral syrups, ointments and dry & powder injections. These formulations support a variety of medical treatments, including anti-diabetic therapies, analgesics, antibiotics, calcium supplements, and vitamin supplements.

The revenue from operations of Amster Labs Ltd grew from ₹96.4939 crores in FY 22 to ₹117.9458 crores in FY 24. Its EBITDA margin grew from 4.95% in FY 22 to 14.61% in FY 24, while PAT margin grew from 1.27% in FY 22 to 7.81% in FY 24. Quality assurance and control, market potential and strong sales, marketing and distribution capabilities have contributed to the company's growth over the years.

Amster Labs Ltd has two manufacturing units situated in Baddi, Distt. Solan, Himachal Pradesh. The total area occupied by its manufacturing facilities expands to more than 75,000 Sq. ft. Its registered office is located at Chandigarh, India. The company holds ISO certification 9001:2015 and ISO 10002:2018 to ensure quality of manufacturing products.

Visit the Registrar’s Website

  • Visit the official website of Skyline Financial Services Pvt Ltd
  • Click on ‘Public Issue’ from ‘Investors’ dropdown
  • Choose ‘Company Name’
  • Enter DPID/Client ID or Application Number or PAN Number
  • Click on ‘Search’ to know the status

Check on the National Stock Exchange Website

The National Stock Exchange (NSE) has an IPO Bid Verification module. You can use it to check the status of Amster Labs Ltd. Go to www.nseindia.com and find the 'Invest' tab. Click on 'Verify IPO Bids' under 'Resources & Tools'. On the NSE IPO Bid Verification page, enter:

  • Company name from dropdown
  • Application number
  • PAN Then click 'Submit' to know the allotment status
  • Step 1: Log in to your Kotak Securities Demat account: Log in to your Demat account to access IPO investments. Next, select the current IPO section.
  • Step 2: Specify IPO details: Enter the number of lots and the price you wish to apply for.
  • Step 3: Enter UPI ID After entering your UPI ID, click submit. This will place your bid with the exchange.
  • Step 4: Mandate Notification: Your UPI app will receive a mandate notification to block funds.
  • Step 5: Approve Request Your funds will be blocked once you approve the mandate request on your UPI.
Apply for Amster Labs IPO